Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 12Genitourinary 11Tumor-Agnostic 4Thoracic 3Breast 3Sarcoma 2Head & Neck 2Gastrointestinal 2CNS 2Endocrine 1

Conditions

Neoplasms 2Neoplasm Metastasis 2

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Standard of Care 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Gemcitabine 6Cyclophosphamide 6Capecitabine 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Surveys and Questionnaires 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
niraparib × Tumor-Agnostic × 90 days × Clear all
NCT04170153 2026-05-07

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

EMD Serono

Phase 1 Active not recruiting
161 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT06077877 2026-04-24

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

GlaxoSmithKline

Phase 1/2 Active not recruiting
42 enrolled
Tumor-Agnostic

Neoplasms

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡